Publication | Closed Access

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Overall Survival AnalysisUrologyAxitinib Versus SorafenibGenitourinary CancerMedicineRandomised Phase 3Cancer TreatmentOncologyRadiation OncologyMolecular Oncology